Retroperitoneal fibrosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Retroperitoneal fibrosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Stopping Prednisolone Early in Patients with Negative FDG-PET/CT and Idiopathic Retroperitoneal Fibrosis https://clinicaltrials.eu/trial/study-on-stopping-prednisolone-early-in-patients-with-negative-fdg-pet-ct-and-idiopathic-retroperitoneal-fibrosis/ Wed, 29 Apr 2026 15:01:15 +0000 https://clinicaltrials.eu/trial/study-on-stopping-prednisolone-early-in-patients-with-negative-fdg-pet-ct-and-idiopathic-retroperitoneal-fibrosis/ This clinical trial is focused on studying a condition known as idiopathic retroperitoneal fibrosis (IRF). This is a rare disease where a fibrous mass forms in the area behind the stomach and intestines, which can cause pain and other symptoms. The treatment being studied in this trial is a medication called prednisone, which is a type of steroid used to reduce inflammation in the body.

The purpose of the study is to understand the effects of stopping steroid treatment early in patients who show no signs of active disease on a special type of scan called FDG-PET/CT. Participants in the study will receive prednisone and will be monitored over a period of time to see if their condition returns after stopping the medication. The study will compare the rate of disease relapse, or return, 12 months after stopping the steroids.

Throughout the study, participants will undergo regular check-ups and imaging tests to monitor their condition. The study will also look at other health factors, such as the occurrence of diabetes, infections, bone fractures, and heart-related events, to ensure a comprehensive understanding of the treatment’s impact. The trial aims to provide valuable insights into the management of IRF and the potential benefits of adjusting steroid treatment based on scan results.

]]>